| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9597281 | MYLAN SPECIALITY LP | Pharmaceutical formulations useful in the treatment of insomnia |
Apr, 2027
(3 years from now) | |
| US9265720 | MYLAN SPECIALITY LP | Pharmaceutical formulations useful in the treatment of insomnia |
Feb, 2031
(7 years from now) | |
Edluar is owned by Mylan Speciality Lp.
Edluar contains Zolpidem Tartrate.
Edluar has a total of 2 drug patents out of which 0 drug patents have expired.
Edluar was authorised for market use on 13 March, 2009.
Edluar is available in tablet;sublingual dosage forms.
Edluar can be used as method of treating insomnia characterized by difficulty with sleep onset.
The generics of Edluar are possible to be released after 25 February, 2031.
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 13 March, 2009
Treatment: Method of treating insomnia characterized by difficulty with sleep onset
Dosage: TABLET;SUBLINGUAL
EDLUAR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic